The German government is “eager to enter into negotiations” with the new US government to agree to changes in US policy that prioritizes the supply of local coronavirus vaccine to US production facilities, according to a document from the Ministry of Health. German health.
In an extensive document published on Tuesday that answered questions from Germany’s Social Democrats, the health ministry sets out why the US was able to guarantee the additional supply of BioNTech / Pfizer vaccines for specific dates, while increasing supply EU is set to come “2021.”
The health ministry says an executive order from the US president means that production facilities in the country are “encouraged to initially make vaccines available for supply in the US”. This means that European production sites for the BioNTech / Pfizer vaccine, as well as the Modern vaccine, need to supply the rest of the world, in addition to Europe.
“Companies, like the federal government, want to enter into negotiations with the new United States administration to make adjustments,” wrote the health ministry.
The document also discussed Germany’s bilateral agreement with BioNTech / Pfizer – something for which the Commission has left Germany out of harm’s way, although it appears to go against the bloc’s efforts to devise a unified vaccine strategy.
What is at issue, explained the Ministry of Health, is the funding received by BioNTech from the German Ministry of Education and Research. That money meant that BioNTech had to supply part of the vaccines to Germany. As a result, the health ministry had to issue a pre-contractual letter of intent in the form of a memorandum of understanding on September 8 for an additional 30 million doses of the vaccine, the health ministry wrote.